Join us for insights and practical guidance on the evolving healthcare legal and policy landscape. Our panel of healthcare litigators discussed current and potential litigation, regulatory developments, and policy shifts shaping strategies for healthcare organizations, life sciences companies, and investors.
Key topics covered include:
IRA Drug Price Negotiation Litigation: Updates on the Medicare Drug Price Negotiation Program and CMS implementation, including key milestones and challenges.
340B Litigation Update: Review of key cases affecting the scope, enforcement, and operations of the 340B Program for covered entities and manufacturers.
Immigrant Access to Care: Updates on litigation and policy trends affecting coverage, eligibility, and enforcement dynamics.
Mifepristone and Challenges to FDA’s Approval: Status of challenges to FDA approval including implications for FDA authority and drug availability.
Potential Challenges to the Make America Healthy Again (MAHA) Agenda: Vaccines and related public health measures.
Developments Related to Conversion Therapy and Gender-Affirming Care for Minors: Updates on litigation against Colorado’s conversion therapy ban, new HHS rules on gender-affirming care, and potential litigation related to those rules.
Who should attend:
In-house counsel and compliance leaders at hospitals, health systems, and physician groups.
Legal, regulatory, and government affairs leaders at health plans and PBMs.
Life sciences and medtech manufacturers, including market access, pricing, and policy teams.
340B covered entities and contract pharmacy leadership.
Revenue cycle, reimbursement, and government programs professionals.
Litigation counsel handling healthcare, ERISA, and administrative law matters.
Investors and advisors focused on healthcare transactions and strategy.
CLE credit for this course is available in New York and California. This program is offering 1.0 Areas of Professional Practice CLE credit in NY, and 1.0 General CLE credit in CA. The program is appropriate for both newly admitted attorneys and experienced attorneys. Please contact us for details.
We use cookies to enhance user experience, improve functionality and performance, and for analysis of website traffic. By clicking “accept”, you agree to the use of cookies. For more information about our cookie policy and the information we collect, please review our Privacy Statement.
Foley Hoag
Email Disclaimer
Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK," you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you.
If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Foley Hoag.
.png?width=689&height=388&ext=.png)
